Status:
COMPLETED
HCV-796 and Midazolam Drug Interaction Study in Healthy Subjects
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Healthy
Eligibility:
All Genders
18-50 years
Phase:
PHASE1
Brief Summary
To evaluate the potential PK interaction of multiple oral doses of HCV-796 and a single oral dose of midazolam when coadministered to healthy subjects.
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Healthy as determined by investigator on the basis of medical history, physical examination, clinical laboratory test results, vital signs and 12-lead ECG.
Exclusion
Key Trial Info
Start Date :
June 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2007
Estimated Enrollment :
38 Patients enrolled
Trial Details
Trial ID
NCT00410254
Start Date
June 1 2007
End Date
August 1 2007
Last Update
December 5 2007
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Gainesville, Florida, United States, 32608
2
Philadelphia, Pennsylvania, United States, 19148